Sema 10mg

$50.00

πŸ”¬ What Is Semaglutide?

  • Semaglutide is a GLP-1 receptor agonist (incretin mimetic).

  • It mimics the hormone GLP-1, which helps regulate blood sugar and appetite.

  • Brand names & approvals:

    • Ozempic β†’ FDA-approved for type 2 diabetes (2017).

    • Rybelsus β†’ oral tablet version, FDA-approved for type 2 diabetes (2019).

    • Wegovy β†’ FDA-approved for chronic weight management (2021).

βš™οΈ Mechanism of Action

  • Stimulates insulin secretion (glucose-dependent).

  • Suppresses glucagon secretion.

  • Slows gastric emptying, prolonging satiety.

  • Acts on the brain’s appetite centers, reducing hunger and food cravings.

πŸ“Š Clinical Benefits

Type 2 Diabetes

  • Lowers A1C by ~1.0–1.5%.

  • Reduces fasting and post-meal glucose.

Weight Loss (Wegovy data)

  • STEP trials (68 weeks):

    • Average 15% body weight reduction at the 2.4 mg weekly dose.

    • Many participants lost >20% of body weight.

Cardiovascular Protection

  • Reduces risk of major adverse cardiovascular events (MACE) in people with T2D and heart disease.

  • In 2023, FDA approved Wegovy for CV risk reduction in overweight/obese patients with established heart disease.

⚠️ Side Effects

Most common:

  • Nausea, vomiting, diarrhea, constipation.

  • Decreased appetite (expected effect).

Other considerations:

  • Rare: pancreatitis, gallbladder disease, GI obstruction.

  • Can increase risk of thyroid C-cell tumors in rodents (contraindicated in patients with personal/family history of medullary thyroid carcinoma or MEN2).

  • May worsen diabetic retinopathy in those with pre-existing disease.

βœ… Key Takeaways

  • Semaglutide = GLP-1 receptor agonist.

  • Approved as Ozempic (T2D), Wegovy (obesity), Rybelsus (oral).

  • Efficacy:

    • A1C reduction: ~1–1.5%.

    • Weight loss: ~15% at 2.4 mg weekly.

  • Dosing: Weekly injections (0.25 β†’ 2.4 mg) or daily oral (3–14 mg).

  • Side effects: Mostly GI; long-term concerns about thyroid, gallbladder, and pancreas (rare).

πŸ”¬ What Is Semaglutide?

  • Semaglutide is a GLP-1 receptor agonist (incretin mimetic).

  • It mimics the hormone GLP-1, which helps regulate blood sugar and appetite.

  • Brand names & approvals:

    • Ozempic β†’ FDA-approved for type 2 diabetes (2017).

    • Rybelsus β†’ oral tablet version, FDA-approved for type 2 diabetes (2019).

    • Wegovy β†’ FDA-approved for chronic weight management (2021).

βš™οΈ Mechanism of Action

  • Stimulates insulin secretion (glucose-dependent).

  • Suppresses glucagon secretion.

  • Slows gastric emptying, prolonging satiety.

  • Acts on the brain’s appetite centers, reducing hunger and food cravings.

πŸ“Š Clinical Benefits

Type 2 Diabetes

  • Lowers A1C by ~1.0–1.5%.

  • Reduces fasting and post-meal glucose.

Weight Loss (Wegovy data)

  • STEP trials (68 weeks):

    • Average 15% body weight reduction at the 2.4 mg weekly dose.

    • Many participants lost >20% of body weight.

Cardiovascular Protection

  • Reduces risk of major adverse cardiovascular events (MACE) in people with T2D and heart disease.

  • In 2023, FDA approved Wegovy for CV risk reduction in overweight/obese patients with established heart disease.

⚠️ Side Effects

Most common:

  • Nausea, vomiting, diarrhea, constipation.

  • Decreased appetite (expected effect).

Other considerations:

  • Rare: pancreatitis, gallbladder disease, GI obstruction.

  • Can increase risk of thyroid C-cell tumors in rodents (contraindicated in patients with personal/family history of medullary thyroid carcinoma or MEN2).

  • May worsen diabetic retinopathy in those with pre-existing disease.

βœ… Key Takeaways

  • Semaglutide = GLP-1 receptor agonist.

  • Approved as Ozempic (T2D), Wegovy (obesity), Rybelsus (oral).

  • Efficacy:

    • A1C reduction: ~1–1.5%.

    • Weight loss: ~15% at 2.4 mg weekly.

  • Dosing: Weekly injections (0.25 β†’ 2.4 mg) or daily oral (3–14 mg).

  • Side effects: Mostly GI; long-term concerns about thyroid, gallbladder, and pancreas (rare).